Making Impressive Motion: Halliburton Company (NYSE:HAL), Worthington Industries (NYSE:WOR), Inuvo (NYSEMKT:INUV), TherapeuticsMD (NYSEMKT:TXMD)

Yahoo! Inc. (NASDAQ:YHOO) ended the last trading day at $36.66. Company weekly volatility is calculated as 1.89% and price to cash ratio as 5.98. Yahoo! Inc. (NASDAQ:YHOO) showed a weekly performance of 0.27%.

Yahoo! Inc. (NASDAQ:YHOO) has set an April 11 deadline to submit preliminary bids for its web business and Asian assets, The Wall Street Journal reported on Monday, citing sources.

On 06 April, Halliburton Company (NYSE:HAL) shares increased 5.93% and was closed at $36.44. HAL EPS growth in last 5 year was -19.10%. Halliburton Company (NYSE:HAL) year to date (YTD) performance is 7.64%.

On 23 March, Halliburton Company (NYSE:HAL)’s bid to buy oil-services rival Baker Hughes Inc. was opposed by the world’s fifth-largest producer Tuesday, a day after being stalled by European regulators.

On 06 April, Worthington Industries, Inc. (NYSE:WOR) shares moved down -1.56% and was closed at $35.38. WOR EPS growth in last 5 year was 14.40%. Worthington Industries, Inc. (NYSE:WOR) year to date (YTD) performance is 18.06%.

Worthington Industries, Inc. (NYSE:WOR) has declared a quarterly dividend of $0.19 per share. The dividend is payable on June 29, 2016, to shareholders of record June 15, 2016.

Inuvo, Inc. (NYSEMKT:INUV) shares advanced 7.65% in last trading session and ended the day at $1.97. INUV Gross Margin is 66.30% and its has a return on assets of 8.60%. Inuvo, Inc. (NYSEMKT:INUV) quarterly performance is -24.81%.

Ladenburg Thalmann began new coverage on Inuvo, Inc. (NYSEMKT:INUV) giving the company a “buy” rating. They now have a USD 5 price target on the stock.

TherapeuticsMD, Inc. (NYSEMKT:TXMD) caters to the Healthcare space. Its weekly performance is 20.22%. On the last day of trading company shares ended up at $7.73. TherapeuticsMD, Inc. (NYSEMKT:TXMD) distance from 50-day simple moving average (SMA50) is 19.15%.

TherapeuticsMD, Inc. (NYSEMKT:TXMD) presented detailed results from the pivotal phase 3 Rejoice Trial for its TX-004HR product candidate in two late-breaking posters at the Endocrine Society’s 98th Annual Meeting and Expo, being held April 1-4, 2016, in Boston.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *